Your cart is currently empty!
Neonatal Abstinence Syndrome (NAS) is a withdrawal syndrome affecting newborns exposed to certain substances, typically opioids, during pregnancy. It primarily impacts the central nervous system (CNS), autonomic nervous system (ANS), and gastrointestinal (GI) systems. Universal screening for substance use is recommended for all pregnant patients to identify risks early.
NAS is commonly caused by maternal use or abuse of opioids, such as heroin, methadone, or prescription pain medications, during pregnancy. Other substances, including antidepressants and benzodiazepines, can also contribute to NAS.
Newborns with NAS may exhibit a range of symptoms due to withdrawal. Symptoms can vary in severity and may include:
NAS is diagnosed based on clinical observation and scoring systems, such as the Finnegan Neonatal Abstinence Scoring System, which rates symptoms to determine the severity and guide treatment.
Substance Exposure | Treatment | Mechanism |
---|---|---|
Opiates | Methadone | Reduces withdrawal symptoms |
Morphine | Manages CNS excitability | |
Buprenorphine | Reduces cravings |
Treatment is tailored to the newborn’s symptom severity. Supportive care, such as swaddling and small, frequent feeds, is essential to comfort and stabilize the newborn.